Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB)
The 1H<sub>3</sub>P<sub>3</sub> TPT regimen was both safe and effective among silicosis patients. Further work is necessary to test the regimen in other high-risk populations.<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT06022146 and NCT03900858.
Authors
- Qichang Zheng (ORCID: https://orcid.org/0000-0003-4570-0863)
- Miao-yao Lin
- Xingyi Zhang (ORCID: https://orcid.org/0000-0001-5387-480X)
- Xi-tian Huang
- J. Q. Li
- Wenhong Zhang (ORCID: https://orcid.org/0000-0002-9165-3212)
- Zhi-Qiang You (ORCID: https://orcid.org/0000-0002-3309-415X)
- Xuefeng Liu (ORCID: https://orcid.org/0000-0002-9922-9627)
- Qingluan Yang (ORCID: https://orcid.org/0009-0001-5180-5568)
- Yanfei Ren (ORCID: https://orcid.org/0000-0002-3987-3269)
- Lingyun Shao (ORCID: https://orcid.org/0000-0001-8514-1029)
- Jidong Gao
- Qiaoling Ruan (ORCID: https://orcid.org/0000-0003-4931-3510)
- Chunlian Ma
- Yuzhou Mao (ORCID: https://orcid.org/0009-0002-7578-3137)
Institutions
- Fudan University (CN)
- Zhejiang Yongning Pharma (China) (CN)
- The First People's Hospital of Wenling (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Emerging Microbes & Infections
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1080/22221751.2025.2502010
- Citations
- 1
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China